We are thrilled to share that Pearce IP’s Founder and CEO, Naomi Pearce, a Finalist in the Lawyers Weekly Women in Law Awards 2024 “Executive of Year”. Now in its 13th year, the...
Aflibercept 19 September 2024 | EU | Sandoz & Samsung Bioepis/Biogen Aflibercept Biosimilars Recommended in Europe At its September meeting, the European Medicines Agency’s...
The battle to claim the earliest valid patent rights to CRISPR gene-editing technology has been fought around the world. In Australia, the most protracted dispute…
Aflibercept 13 September 2024 | KR | Alteogen Submits Application for Biosimilar Aflibercept in Korea On 13 September 2024, Korea Biomedical Review reported that Korea-based...
Adalimumab 1 September 2024 | AU | Pfizer’s Biosimilar Adalimumab PBS-Listed in Australia On 1 September 2024, the PBS published its Summary of Changes, which included listing...
We congratulate Naomi Pearce, Pearce IP’s CEO and Founder (Lawyer, Patent and Trade Mark Attorney) on her 2024 IAM Strategy 300 ranking in three categories: Legal;...
CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.
Equal Pay Day is the 50th day of the financial year and marks the number of extra days that women would need to work to earn the same as men did last financial year. As we...
16 August 2024 | AU | Janssen Sues Samsung Bioepis for Patent Infringement in Australian Court On 16 August 2024, Janssen Biotech, Inc and Janssen-Cilag Pty Ltd commenced patent...
We are delighted to announce that Pearce IP’s founder and CEO, Naomi Pearce, has been honoured by Australasian Lawyer in The Most Influential Lawyers in Australia list for...
The IPKat has received and is pleased to host the following guest contribution by Kimberley Evans (Pearce IP) regarding a recent Australian decision concerning inter alia the honest concurrent use and own name defences under Australian trade mark law. Here’s what Kimberley writes:
Fanatics about trade mark infringement, cancellation and honest concurrent use in Australia
9 August 2024 | Sandoz Reports Q2/24 and Half Year Financial Results - 37% Biosimilar Growth On 9 August 2024, Sandoz announced its Q2 2024 sales and financial results for half...
2 August 2024 | AU | Novo Nordisk Launches Wegovy® (Semaglutide) in Australia On 2 August 2024, Australia’s Therapeutic Goods Administration announced that, according to Novo...
26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UCOn 26 July 2024, AbbVie announced European Commission approval of Skyrizi®...
CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that the European Medicines Agency (EMA) accepted its marketing...
How to Handle Roadblocks with an Australian Patent Examiner
Apple Inc. [2024] APO 25 (25 June 2024)
Amazentis SA [2024] APO 27 (28 June 2024)
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's Disease On 11 and 12 July 2024, respectively, Eisai and...
Elanco Australasia Pty Ltd v Abbey Laboratories Pty Ltd [2024] FCA 640
WIPR Leaders released its annual global guide to the world’s leading practitioners last week, and we are delighted to have 8 Pearce IP leaders across Australia and New Zealand...
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical Dialogues reported that Zydus Life Sciences’ biosimilar...
We are thrilled to announce that Pearce IP has been honoured as Australasian Lawyer’s 2024 The Best Boutique Intellectual Property Law Firms in Australia!
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech has announced the completion of phase 1 clinical trials of...
We are thrilled to announce that Pearce IP has been honoured as Australasian Lawyer’s 2024 The Best Boutique Intellectual Property Law Firms in Australia!
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
